RxDoctor Payments Data

Eric Howell

Dermatology · Greenville, NCNPI 1285834788

Payments from drug & device makers

$5,088in general payments, 2019–2025

Across 220 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Merz North America, Inc.$550
  • LEO Pharma Inc.$466
  • Johnson & Johnson$443
  • Amgen$188
  • Novartis$166
  • plus $626 from 16 others

What the payments were for

  • Consulting fees$1,00020%
  • Food & beverage$3,86576%
  • Education$2234%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,088 in reported general payments places this provider in the 65th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$532,966
Medicare patients
1,833
Services billed
11,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyriziRisankizumab-Rzaa13$274,150
Dupixent SyringeDupilumab60$272,947
StelaraUstekinumab12$202,976
Cosentyx Sensoready (2 Pens)Secukinumab26$188,780
OtezlaApremilast36$185,249
Humira(Cf) PenAdalimumab14$181,612
Cosentyx (2 Syringes)Secukinumab11$79,869
Acitretin53$20,364
Clobetasol Propionate311$11,292
Fluorouracil153$9,821
Fluocinonide85$4,872
Mometasone Furoate280$4,369
Tretinoin54$3,380
Triamcinolone Acetonide265$3,240
Calcipotriene21$2,962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSkyrizi$2,649$274,15013 claims
Johnson & JohnsonStelara$443$202,97612 claims
AmgenOtezla$188$185,24936 claims
NovartisCosentyx (2 Syringes)$166$79,86911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 475 dermatology providers in North Carolina.

Other dermatology in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →